Proteins of Leishmania (Viannia) shawi confer protection associated with Th1 immune response and memory generation

Particle and Fibre Toxicology

Márcia D Laurenti⁵  Carlos EP Corbett⁵  Adriana Paes-Leme⁴  Marcos H Toyama¹  Bianca BA Santos²  Esper G Kallás²  Karina Carvalho²  Alexis Bonfim-Melo¹  Maria LAC Bordon⁵  Ana Kely Carvalho⁵  Luiz Felipe D Passero³ 

[1] Campus Experimental do Litoral Paulista, Universidade Estadual Paulista, São Vicente, São Paulo, Brazil;Division of Clinical Immunology and Allergy, (LIM-60), University of São Paulo, São Paulo, Brazil;Depto. de Patologia da Faculdade de Medicina da Universidade de São Paulo, Laboratório de Patologia de Moléstias Infecciosas (LIM-50), Av. Dr. Arnaldo, 455, Cerqueira César, SP 01246-903, Brazil;Brazilian Biosciences National Laboratory, CNPEM, Campinas, Brazil;Depto. de Patologia da Faculdade de Medicina da Universidade de São Paulo, Laboratório de Patologia de Moléstias Infecciosas (LIM-50), São Paulo, Brazil

关键词: Long-term protection;    Cellular immune response;    Immunization;    Proteic fraction;    Leishmania (Viannia) shawi;   

Others  :  1233012
DOI  :  10.1186/1756-3305-5-64

 received in 2011-11-01, accepted in 2012-03-30,  发布年份 2012

【 摘 要 】

Background

Leishmania (Viannia) shawi parasite was first characterized in 1989. Recently the protective effects of soluble leishmanial antigen (SLA) from L. (V.) shawi promastigotes were demonstrated using BALB/c mice, the susceptibility model for this parasite. In order to identify protective fractions, SLA was fractionated by reverse phase HPLC and five antigenic fractions were obtained.

Methods

F1 fraction was purified from L. (V.) shawi parasite extract by reverse phase HPLC. BALB/c mice were immunized once a week for two consecutive weeks by subcutaneous routes in the rump, using 25 μg of F1. After 1 and 16 weeks of last immunization, groups were challenged in the footpad with L. (V.) shawi promastigotes. After 2 months, those same mice were sacrificed and parasite burden, cellular and humoral immune responses were evaluated.

Results

The F1 fraction induced a high degree of protection associated with an increase in IFN-γ, a decrease in IL-4, increased cell proliferation and activation of CD8⁺T lymphocytes. Long-term protection was acquired in F1-immunized mice, associated with increased CD4⁺ central memory T lymphocytes and activation of both CD4⁺ and CD8⁺ T cells. In addition, F1-immunized groups showed an increase in IgG2a levels.

Conclusions

The inductor capability of antigens to generate memory lymphocytes that can proliferate and secrete beneficial cytokines upon infection could be an important factor in the development of vaccine candidates against American Tegumentary Leishmaniasis.

【 授权许可】

   
2012 Passero et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Silveira FT, Lainson R, De Castro Gomes CM, Laurenti MD, Corbett CE: Immunopathogenic competences of Leishmania (V.) braziliensis and L. (L.) amazonensis in American cutaneous leishmaniasis. Parasite Immunol 2009, 31:423-431.
• [2]Crescente JA, Silveira FT, Lainson R, Gomes CM, Laurenti MD, Corbett CE: A cross-sectional study on the clinical and immunological spectrum of human Leishmania (L.) infantum chagasi infection in the Brazilian Amazon region. Trans R Soc Trop Med Hyg 2009, 103:1250-1256.
• [3]Carvalho Mde L, de Andrade AS, Fontes CJ, Hueb M, de Oliveira Silva S, Melo MN: Leishmania (Viannia) braziliensis is the prevalent species infecting patients with tegumentary leishmaniasis from Mato Grosso State, Brazil. Acta Trop 2006, 98:277-285.
• [4]Morrison B, Mendoza I, Delgado D, Reyes Jaimes O, Aranzazu N, Paniz Mondolfi AE: Diffuse (anergic) cutaneous leishmaniasis responding to amphotericin B. Clin Exp Dermatol 2010, 35:e116-9.
• [5]Shaw JJ, Ishikawa EA, Lainson R, Braga RR, Silveira FT: Cutaneous leishmaniasis of man due to Leishmania (Viannia) shawi Lainson, de Souza, Póvoa, Ishikawa & Silveira, in Pará State, Brazil. Ann Parasitol Hum Comp 1991, 66:243-246.
• [6]Lainson R, Shaw JJ: Epidemiology and ecology of leishmaniasis in Latin-America. Nature 1978, 273:595-600.
• [7]Khamesipour A, Dowlati Y, Asilian A, Hashemi-Fesharki R, Javadi A, Noazin S, Modabber F: Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine 2005, 23:3642-3648.
• [8]Pessoa SB, Pestana BR: Ensaio sobre a vacinação preventiva na leishmaniose tegumentar americana, com germes mortos. Rev Biol Hyg 1940, 10:112-118.
• [9]Antunes CM, Mayrink W, Magalhães PA, Costa A, Melo MN, Dias M, Michalick MSM, Williams P, Lima AO, Vieira JBF, Schettini APM: Controlled field trials of a vaccine against New World cutaneous leishmaniasis. Int J Epidemiol 1986, 15:572-580.
• [10]Palatnik-de-Sousa CB, Paraguai-de-Souza E, Gomes EM, Borojevic R: Experimental murine Leishmania donovani infection: immunoprotection by the fucose-mannose ligand (FML). Braz J Med Biol Res 1994, 27:547-551.
• [11]Masih S, Arora SK, Vasishta RK: Efficacy of Leishmania donovani ribosomal P1 gene as DNA vaccine in experimental visceral leishmaniasis. Exp Parasitol 2011, 129:55-64.
• [12]Rodrigues MM, Mendonça-Previato L, Charlab R, Barcinski MA: The cellular immune response to a purified antigen from Leishmania mexicana subsp. amazonensis enhances the size of the leishmanial lesion on susceptible mice. Infect Immun 1987, 55:3142-3148.
• [13]Baum C, von Kalle C: Gene therapy targeting hematopoietic cells: better not leave it to chance. Acta Haematol 2003, 110:107-119.
• [14]Palatnik-de-Sousa CB, Silva-Antunes I, Morgado Ade A, Menz I, Palatnik M, Lavor C: Decrease of the incidence of human and canine visceral leishmaniasis after dog vaccination with Leishmune in Brazilian endemic areas. Vaccine 2009, 27:3505-3512.
• [15]Lemesre JL, Holzmuller P, Cavaleyra M, Gonçalves RB, Hottin G, Papierok G: Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes. Vaccine 2005, 23:2825-2840.
• [16]Passero LF, Marques C, Vale-Gato I, Corbett CE, Laurenti MD, Santos-Gomes G: Analysis of the protective potential of antigens released by Leishmania (Viannia) shawi promastigotes. Arch Dermatol Res 2012, 304:47-55.
• [17]Palatnik-de-Sousa CB, Day MJ: One Health: the global challenge of epidemic and endemic leishmaniasis. Parasit Vectors 2011, 4:197. BioMed Central Full Text
• [18]Mora AM, Mayrink W, Costa RT, Costa CA, Genaro O, Nascimento E: Protection of C57BL/10 mice by vaccination with association of purified proteins from Leishmania (Leishmania) amazonensis. Rev Inst Med Trop Sao Paulo 1999, 41:243-248.
• [19]Pinheiro RO, Pinto EF, de Matos Guedes HL, Filho OA, de Mattos KA, Saraiva EM, de Mendonça SC, Rossi-Bergmann B: Protection against cutaneous leishmaniasis by intranasal vaccination with lipophosphoglycan. Vaccine 2006, 24:5645-5652.
• [20]Gorczynski RM: Immunization of susceptible BALB/c mice against Leishmania braziliensis. I. Resistance induced using as immunogen adherent or nonadherent cells from infected mice. Cell Immunol 1985, 94:1-10.
• [21]Travi BL, Osorio Y, Saravia NG: The inflammatory response promotes cutaneous metastasis in hamsters infected with Leishmania (Viannia) panamensis. J Parasitol 1996, 82:454-457.
• [22]Passero LF, Sacomori JV, Tomokane TY, Corbett CE, da Silveira FT, Laurenti MD: Ex vivo and in vivo biological behavior of Leishmania (Viannia) shawi. Parasitol Res 2009, 105:1741-1747.
• [23]Jayakumar A, Castilho TM, Park E, Goldsmith-Pestana K, Blackwell JM, McMahon-Pratt D: TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia). PLoS Negl Trop Dis 2011, 5:e1204.
• [24]Passero LF, Da Costa Bordon ML, De Carvalho AK, Martins LM, Corbett CE, Laurenti MD: Exacerbation of Leishmania (Viannia) shawi infection in BALB/c mice after immunization with soluble antigen from amastigote forms. APMIS 2010, 118:973-981.
• [25]Cupolillo E, Grimaldi G Jr, Momen H: A general classification of New World Leishmania using numerical zymotaxonomy. Am J Trop Med Hyg 1994, 50:296-311.
• [26]Toyama MH, Toyama DO, Passero LF, Laurenti MD, Corbett CE, Tomokane TY, Fonseca FV, Antunes E, Joazeiro PP, Beriam LO, Martins MA, Monteiro HS, Fonteles MC: Isolation of a new L-amino acid oxidase from Crotalus durissus cascavella venom. Toxicon 2006, 47:47-57.
• [27]Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
• [28]Hanna SL, Sherman NE, Kinter MT, Goldberg JB: Comparison of proteins expressed by Pseudomonas aeruginosa strains representing initial and chronic isolates from a cystic fibrosis patient: an analysis by 2-D gel electrophoresis and capillary column liquid chromatography-tandem mass spectrometry. Microbiology 2000, 146:2495-2508.
• [29]Rhee EG, Mendez S, Shah JA, Wu CY, Kirman JR, Turon TN, Davey DF, Davis H, Klinman DM, Coler RN, Sacks DL, Seder RA: Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against Leishmania major infection. J Exp Med 2002, 195:1565-1573.
• [30]Passero LF, Marques C, Vale-Gato I, Corbett CE, Laurenti MD, Santos-Gomes G: Histopathology, humoral and cellular immune response in the murine model of Leishmania (Viannia) shawi. Parasitol Int 2010, 59:159-165.
• [31]Ahmed SA, Gogal RM Jr, Walsh JE: A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J Immunol Methods 1994, 170:211-224.
• [32]Gomes-Pereira S, Rodrigues OR, Santos-Gomes GM: Dynamics of CD62L/CD45RB CD4+ and CD8+ lymphocyte subsets in hepatic and splenic tissues during murine visceral leishmaniasis. Immunol Lett 2004, 95:63-70.
• [33]Stober CB, Lange UG, Roberts MT, Gilmartin B, Francis R, Almeida R, Peacock CS, McCann S, Blackwell JM: From genome to vaccines for leishmaniasis: screening 100 novel vaccine candidates against murine Leishmania major infection. Vaccine 2006, 24:2602-2616.
• [34]Rey-Ladino JA, Joshi PB, Singh B, Gupta R, Reiner NE: Leishmania major: molecular cloning, sequencing, and expression of the heat shock protein 60 gene reveals unique carboxy terminal peptide sequences. Exp Parasitol 1997, 85:249-263.
• [35]Dey A, Sharma P, Redhu NS, Singh S: Kinesin motor domain of Leishmania donovani as a future vaccine candidate. Clin Vaccine Immunol 2008, 15:836-842.
• [36]Dey A, Kumar U, Sharma P, Singh S: Immunogenicity of candidate chimeric DNA vaccine against tuberculosis and leishmaniasis. Vaccine 2009, 27:5152-5160.
• [37]Strehl B, Seifert U, Krüger E, Heink S, Kuckelkorn U, Kloetzel PM: Interferon-gamma, the functional plasticity of the ubiquitin-proteasome system, and MHC class I antigen processing. Immunol Rev 2005, 207:19-30.
• [38]Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE: The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 1999, 17:701-738.
• [39]Beyrodt CG, Pinto AR, Freymüller E, Barbiéri CL: Characterization of an antigen from Leishmania amazonensis amastigotes able to elicit protective responses in a murine model. Infect Immun 1997, 65:2052-2059.
• [40]Stäger S, Alexander J, Kirby AC, Botto M, Rooijen NV, Smith DF, Brombacher F, Kaye PM: Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8 T-cell responses. Nat Med 2003, 9:1287-1292.
• [41]Carvalho LH, Sano G, Hafalla JC, Morrot A, Curotto de Lafaille MA, Zavala F: IL-4-secreting CD4 T cells are crucial to the development of CD8 T-cell responses against malaria liver stages. Nat Med 2002, 8:166-170.
• [42]Holaday BJ, Pompeu MM, Jeronimo S, Texeira MJ, Sousa Ade A, Vasconcelos AW, Pearson RD, Abrams JS, Locksley RM: Potential role for interleukin-10 in the immunosuppression associated with kalaazar. J Clin Invest 1993, 92:2626-2632.
• [43]Tabatabaee PA, Abolhassani M, Mahdavi M, Nahrevanian H, Azadmanesh K: Leishmania major: Secreted antigens of Leishmania major promastigotes shift the immune response of the C57BL/6 mice toward Th2 in vitro. Exp Parasitol 2011, 127:46-51.
• [44]Whitmire JK, Tan JT, Whitton JL: Interferon-gamma acts directly on CD8+ T cells to increase their abundance during virus infection. J Exp Med 2005, 201:1053-1059.
• [45]Sprent J, Surh CD: Normal T cell homeostasis: the conversion of naive cells into memory-phenotype cells. Nat Immunol 2011, 12:478-484.
• [46]Powrie F, Correa-Oliveira R, Mauze S, Coffman RL: Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J Exp Med 1994, 179:589-600.
• [47]Costa RP, Gollob KJ, Machado PR, Bacellar OA, Almeida RP, Barral A, Barral-Netto M, Carvalho EM, Dutra WO: Adhesion molecule expression patterns indicate activation and recruitment of CD4+ T cells from the lymph node to the peripheral blood of early cutaneous leishmaniasis patients. Immunol Lett 2003, 90:155-159.
• [48]Croft M, Carter L, Swain SL, Dutton RW: Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med 1994, 180:1715-1728.
• [49]Freitas do Rosário AP, Muxel SM, Rodríguez-Málaga SM, Sardinha LR, Zago CA, Castillo-Méndez SI, Alvarez JM, D'Império Lima MR: Gradual decline in malaria-specific memory T cell responses leads to failure to maintain long-term protective immunity to Plasmodium chabaudi AS despite persistence of B cell memory and circulating antibody. J Immunol 2008, 181:8344-8355.
• [50]Stefani MM, Müller I, Louis JA: Leishmania major-specific CD8+ T cells are inducers and targets of nitric oxide produced by parasitized macrophages. Eur J Immunol 1994, 24:746-752.
• [51]Ruiz JH, Becker I: CD8 cytotoxic T cells in cutaneous leishmaniasis. Parasite Immunol 2007, 29:671-678.
• [52]Colmenares M, Kima PE, Samoff E, Soong L, McMahon-Pratt D: Perforin and gamma interferon are critical CD8+ T-cell-mediated responses in vaccine-induced immunity against Leishmania amazonensis infection. Infect Immun 2003, 71:3172-3182.
• [53]Herath S, Kropf P, Müller I: Cross-talk between CD8(+) and CD4(+) T cells in experimental cutaneous leishmaniasis: CD8(+) T cells are required for optimal IFN-gamma production by CD4(+) T cells. Parasite Immunol 2003, 25:559-567.
• [54]Akdis M, Burgler S, Crameri R, Eiwegger T, Fujita H, Gomez E, Klunker S, Meyer N, O'Mahony L, Palomares O, Rhyner C, Quaked N, Schaffartzik A, Van De Veen W, Zeller S, Zimmermann M, Akdis CA, Akdis CA: Interleukins, from 1 to 37, and interferon-γ: Receptors, functions, and roles in diseases. J Allergy Clin Immunol 2011, 127:701-721. Akdis et al 2011
• [55]Coffman RL, Lebman DA, Rothman P: Mechanism and regulation of immunoglobulin isotype switching. Adv Immunol 1993, 54:229-270.